Events at Borealis
Education and Community in Psychedelic Science
In addition to the main conference, we are planning a series of satellite events, workshops, webinars and gatherings designed to expand your understanding and help you connect with the psychedelic science community. More events will be added soon - subscribe to our newsletter and we'll keep you updated!
Led by ACT researcher Jason Luoma, PhD, this full-day workshop at Elite Hotel Marina Tower teaches clinicians how to apply ACT’s six core processes, acceptance, defusion, present-moment awareness, self-as-context, values, and committed action, to the preparation, dosing, and integration phases of psilocybin, MDMA, and ketamine-assisted therapy. Through concise lectures and hands-on exercises, you’ll learn evidence-based strategies for fostering psychological flexibility, navigate key ethical and cultural considerations, and build practical skills, all over a gourmet lunch and traditional Swedish fika.
Led by psychiatrist and psychopharmacology expert Dr. Julie Holland in conversation with clinical psychologist Filip Bromberg, this webinar examines the fallout from the FDA’s unexpected 2024 rejection of MDMA-assisted therapy and explores what comes next for clinicians and researchers. You’ll dive into whether further Phase 3 trials are needed, the clinical and ethical dilemmas at hand, harm-reduction strategies, and the therapeutic relationship’s role in MDMA therapy. Join us for a critical, forward-looking dialogue on lessons for Sweden and the global psychedelic community as we navigate this pivotal moment.
Led by clinical psychologist Jason Luoma, PhD, in conversation with Filip Bromberg, this webinar explores the evolving role of psychedelics in treating anxiety disorders highlighting Jason’s landmark MDMA-assisted therapy trial for Social Anxiety Disorder while unpacking how Acceptance and Commitment Therapy (ACT) can extend treatment beyond MDMA by targeting avoidance and fostering psychological flexibility. They’ll discuss recent clinical findings, ethical and harm-reduction considerations, and practical frameworks for responsibly integrating psychedelics and ACT into practice, offering clinicians clear, actionable insights for the next frontier in anxiety care.
